An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris

Study Identifier
225678-005
CT.gov Identifier
NCT01785836
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Study Details

Medical Condition
  • Dermatology - Acne
    • Study Drug
  • Dapsone Formulation A
  • Dapsone Formulation B
  • Dapsone Formulation C
  • Dapsone 5% Gel
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    12 - 35 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Participation in Allergan study 225678-004
    Exclusion Criteria:
    * Anticipates the need for surgery or hospitalization during the study

    Protocol Summary

    This study will assess the safety, tolerability, and efficacy of dapsone in subjects with acne vulgaris following 12 weeks of treatment.

    Study Locations

    No locations found.